TCR2 Therapeutics Revenue and Competitors

Boston, MA USA

Location

$173.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • TCR2 Therapeutics's estimated annual revenue is currently $4.5M per year.(i)
  • TCR2 Therapeutics received $125.0M in venture funding in March 2018.
  • TCR2 Therapeutics's estimated revenue per employee is $42,009
  • TCR2 Therapeutics's total funding is $173.3M.
  • TCR2 Therapeutics's current valuation is $153.3M. (January 2022)

Employee Data

  • TCR2 Therapeutics has 107 Employees.(i)
  • TCR2 Therapeutics grew their employee count by -29% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

TCR2 is an innovative immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer.

keywords:Biotechnology,Healthcare

$173.3M

Total Funding

107

Number of Employees

$4.5M

Revenue (est)

-29%

Employee Growth %

$153.3M

Valuation

N/A

Accelerator

TCR2 Therapeutics News

2022-04-17 - Zacks: Brokerages Expect TCR2 Therapeutics Inc. (NASDAQ ...

Zacks: Brokerages Expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) Will Announce Earnings of -$0.74 Per Share. Posted by admin on Apr 20th, 2022.

2022-03-30 - TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Benzinga

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from...

2022-03-30 - TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC ...

TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC-T Cell Therapies. Partnership enables TCR2 to evaluate multiple allogeneic candidates...

2019-09-12 - TCR2 Therapeutics, NCI Team Up to Test TC-210 ...

TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, ...

2019-08-31 - TCR2 Therapeutics Sees Hammer Chart Pattern: Time to Buy?

TCR² Therapeutics Inc. TCRR has been struggling lately, but the selling pressure may be coming to an end soon. That is because TCRR ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.5M107N/AN/A
#2
$10.9M1078%N/A
#3
$15M1075%$31M
#4
$15M107N/AN/A
#5
N/A10880%N/A

TCR2 Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-12-12$44.5MAMPM CapitalArticle
2018-03-22$125.0MB6 Dimensions CapitalArticle